Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is also asking what forms of artifical intelligence can be slotted in at what stages in the process. AI-powered drug repurposing has seen some candidates enter clinical stage testing, but its still unclear whether the technology is already powerful enough for de novo molecule discovery.
Rentschler Biopharma SE announced today the appointment of Dr. Christian Hunzinger as the new Senior Vice President Project Management, effective from January 15, 2019.
Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
Valbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development.
Its the most commonly cultivated, trafficked and abused illicit drug worldwide, and theres still a lot of social stigma attached to the recreational use of pot. But its slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.